cirmtuzumab
mAbexperimental
Cirmtuzumab is an anti-ROR1 humanised monoclonal antibody. — Wikipedia
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02222688)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Immune System Diseases · Phase 3
- Immunoproliferative Disorders · Phase 3
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Lymphatic Diseases · Phase 3
- Lymphoma · Phase 3
- Lymphoma, B-Cell · Phase 3
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 3
- Lymphoma, Non-Hodgkin · Phase 3
- Lymphoproliferative Disorders · Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 2
Mechanism of action
ROR1 inhibitor
Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCirmtuzumab ↗
- ChEMBLCHEMBL4297728 ↗
Also known as
- cirmtuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05431179 | Phase 3 | Sep 30, 2022 | Oncternal Therapeutics, Pharmacyclics |
| NCT05156905 | Phase 2 | Feb 28, 2022 | University of California, San Diego |
| NCT04501939 | Phase 2 | Aug 6, 2020 | Oncternal Therapeutics, University of California, San Diego |
| NCT02776917 | Phase 1 | Jan 1, 2018 | University of California, San Diego |
| NCT03088878 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | University of California, San Diego |
| NCT02860676 | Phase 1 | Sep 1, 2016 | University of California, San Diego, University of California, San Francisco |
| NCT02222688 | Phase 1 | Aug 1, 2014 | University of California, San Diego, University of California, San Francisco |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, San Diego | Academic/Hospital | 6 | 6 | 2 | 2014 |
| Oncternal Therapeutics | For profit | 2 | 1 | 2 | 2020 |
| University of California, San Francisco | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Pharmacyclics | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1